CW3657

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: CW3657
• 英文别名: 1-Benzyl-4-(3,4-dichlorobenzyl)piperazine；1-benzyl-4-[(3,4-dichlorophenyl)methyl]piperazine
• 化学式: C₁₈H₂₀Cl₂N₂
• 分子量: 335.276
• InChiKey: IUNCEHMYVOKILY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-苄基哌嗪 、 alkaline earth salt of/the/ methylsulfuric acid 在 碳酸氢钠 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 CW3657
  参考文献：
  名称：

  1,4-Dibenzylpiperazines possess anticocaine activity

  摘要：

  N,N-Dibenzylpiperazines have high affinity for sigma receptors, and we aimed to increase their anticocaine activity by introducing substituents known to enhance such activity in other sigma ligands. Ligands with high affinity for sigma-1 receptors resulted, but their activity in attenuating cocaine-induced convulsions did not cot-relate with sigma-l binding affinity, and may be more closely related to their sigma-2 binding affinities. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)01034-x

文献信息

• COMPOUNDS FOR TREATING MYELIN RELATED DISORDERS
  申请人：Case Western Reserve University

  公开号：US20210353642A1

  公开（公告）日：2021-11-18

  Disclosed is a pharmaceutical composition comprising a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a myelin related disorder in a subject, the method comprising administering to the subject an effective amount of a compound of Structural Formula (I) or a pharmaceutical composition comprising the compound of Structural Formula (I). The variables of Structural Formula (I) are described herein.